OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Review of Anti-Infective Therapy is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis	135
Challenges in preserving antibiotic effectiveness: time for a novel approach	90
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex	66
Neonatal ocular prophylaxis in the United States: is it still necessary?	57
Visceral leishmaniasis elimination in India: progress and the road ahead	53
A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future	48
Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review	45
Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin	43
The emergence of Japanese encephalitis as a public health concern in New South Wales Australia	38
Part 1: Understanding the role of Malassezia spp. in skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and a	38
Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720	38
The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies	38
The global surge of drug-resistant infections and what it reveals about our failing defenses	37
A multicenter study of antibiotic resistance patterns of bacterial isolates from patients with hematological and solid cancers	37
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies	36
Response to: ‘letter to the editor: “A multifaceted strategy is needed to limit the over-the-counter sale of antimicrobials “’	35
Tackling antimicrobial resistance in sub-Saharan Africa: challenges and opportunities for implementing the new people-centered WHO guidelines	35
Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections?	34
Difficile to treat: advanced management strategies in difficult to treat Clostridioides difficile infections	34
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?	32
Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?	29
Tineas caused by hedgehogs due to Trichophyton erinacei an ascending agent of dermatophytosis	28
Treatment of vaginitis caused by non-albicans Candida species	27
Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges	27
New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections	27

Identifying predictors of treatment failure with community-acquired pneumonia: an update